A pharmaceutical company has initiated a voluntary recall of more than half a million bottles of its blood pressure medication distributed in the U.S., after finding that the bottles contained higher than acceptable levels of a carcinogen.<\/p>\n
Teva Pharmaceuticals has recalled more than 580,000 bottles of prazosin hydrochloride capsules, a medication used to manage hypertension, a report by federal regulators<\/a> shows. The company is headquartered in Israel<\/a>, but the recall is connected to its U.S. operations.<\/p>\n The recall, according to a page on the U.S. Food and Drug Administration website<\/a>, impacts three different dosages: 1, 2 and 5 milligrams. The recalled bottles have expiration dates ranging from October 2025 through February 2027.<\/p>\n The impacted bottles contain higher than acceptable levels of a carcinogenic substance. The FDA classified the risk as Class II<\/a>. That class of risk, according to the FDA, indicates that the recalled medication \u201cmay cause temporary or medically reversible adverse health consequences\u201d or that \u201cthe probability of serious adverse health consequences is remote.\u201d<\/p>\n Business Briefing<\/p>\n